Adaptive Trial Uses AI to Pinpoint Top COVID-19 Treatments
April 10, 2020
The REMAP-CAP trial is implementing artificial intelligence in a bid to rapidly identify the best possible treatments for COVID-19 patients, STAT reports.
According to the report, organizers of the adaptive trial are feeding the software data from more than 50 hospitals to discover which drugs were best for which types of patients.
“It puts a high burden on the operational realities of getting data in real time for all of these sites so that you can then learn from it,” Clinical Ink CEO Ed Seguine tells STAT.
To read the full report on STAT, click here.